The authors thank all the participants who volunteered for this study.
Supported by grants from the Swiss National Science Foundation (323530_199395 to PV) and the National Center of Competence in Research Molecular Systems Engineering (51NF40-182895 to HS); by the Wellcome Trust (PINNACLE study); and by the Foundation Fighting Blindness Clinical Research Institute (ProgStar study). All arrangements were reviewed and approved by the University of Basel and the board of directors of the Institute of Molecular and Clinical Ophthalmology Basel in accordance with their conflict-of-interest policies. Compensation is being negotiated and administered as grants by the University of Basel, which receives them on its proper accounts. Funding organizations had no influence on the design, performance, or evaluation of the current study.
Disclosure: P. Valmaggia, Swiss National Science Foundation (Grant 323530_199395) (F), AlumniMedizin Basel (F); N. Inglin, None; P. Kaiser, Supercomputing Systems AG, Zurich, Switzerland (E); H.P.N. Scholl, Swiss National Science Foundation (Project funding: “Developing novel outcomes for clinical trials in Stargardt disease using structure/function relationship and deep learning” #310030_201165, and National Center of Competence in Research Molecular Systems Engineering: “NCCR MSE: Molecular Systems Engineering (phase II)” #51NF40-182895) (F), the Wellcome Trust (PINNACLE study) (F), and the Foundation Fighting Blindness Clinical Research Institute (ProgStar study) (F), Astellas Pharma Global Development, Inc./Astellas Institute for Regenerative Medicine (S), Boehringer Ingelheim Pharma GmbH & Co (S), Gyroscope Therapeutics Ltd. (S), Janssen Research & Development, LLC (Johnson & Johnson) (S), Novartis Pharma AG (CORE) (S), Okuvision GmbH (S), and Third Rock Ventures, LLC (S), Gerson Lehrman Group (C), Guidepoint Global, LLC (C), and Tenpoint Therapeutics Limited (C), Data Monitoring and Safety Board/Committee of Belite Bio (CT2019-CTN-04690-1), ReNeuron Group Plc/Ora Inc. (NCT02464436), F. Hoffmann-La Roche Ltd (VELODROME trial, NCT04657289; DIAGRID trial, NCT05126966) and member of the Steering Committee of Novo Nordisk (FOCUS trial; NCT03811561) (N); P.M. Maloca, Roche (C), MIMO AG (O), VisionAI (O)